Every material Form 8-K MAIA Biotechnology, Inc. has filed with the SEC since April 16, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MAIA Biotechnology filed a Form 8-K furnishing a company presentation (Exhibit 99.1) and a summary (Exhibit 99.2) that management may use in investor presentations on or after October 6, 2026. The filing contains no financial results, guidance, or new transaction terms, and the company states the materials are summary information to be read alongside its other SEC filings.
Presentation and summary were both posted to the company website on October 6, 2026.
Filing covers Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Exhibits 99.1, 99.2 and 104).
Materials contain forward-looking statements tied to preclinical and clinical studies, regulatory approvals and market acceptance.
MAIA Biotechnology suspended sales of its common stock under an at-the-market offering agreement with H.C. Wainwright & Co. and gave notice that it is terminating the agreement, effective seven business days after May 14, 2026. Under the program, the company has sold 3,116,012 shares for gross proceeds of approximately $5,680,924 since the March 28, 2025 prospectus supplement covering up to $11,200,000. The filing does not give a reason for the termination, and ending the program means the company will no longer sell new shares through this channel.
Agreement dated February 14, 2024, with H.C. Wainwright & Co., LLC; sales suspended May 14, 2026
Termination effective seven business days after May 14, 2026
Shares sold under the program: 3,116,012 for gross proceeds of approximately $5,680,924
Prospectus supplement dated March 28, 2025 covered up to $11,200,000
MAIA Biotechnology said it activated its first U.S. clinical site, Summit Medical Group in New Jersey, for the expansion of its Phase 2 THIO-101 trial of ateganosine in third-line non-small cell lung cancer. The company plans four more U.S. sites in 2026, and the U.S. portion of third-line testing is funded by a $2.3 million NIH grant; the filing reports no financial results or guidance.
First U.S. site activated: Summit Medical Group in New Jersey, with principal investigator Charles J. Kim, M.D.
MAIA intends to open four additional U.S. sites in 2026.
U.S. third-line evaluation is funded by a $2.3 million grant from the National Institutes of Health.
Trial is ongoing in Europe and Asia with 44 active sites in 6 countries.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MAIA Biotechnology, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →